Summarized by Masters of Longevity from PR Newswire.
A news article about a university core facility licensing foundational CRISPR/Cas9 patents to expand its genome‑engineering service offerings for researchers.
Key Takeaways
- KU Leuven's Leuven Viral Vector Core secured a non-exclusive license to ERS Genomics' foundational CRISPR/Cas9 patent portfolio.
- The license allows the core to offer CRISPR/Cas9-mediated genome engineering including engineered cellular disease models and iPSC lines.
- ERS Genomics' CVC patent estate includes over 130 issued patents and provides licensed access for research tools and services.
